Changchun GeneScience Pharmaceutical Co., Ltd. d/b/a GenSci Pharma, a top biopharma company in China and lead player globally in children and women's health, today announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, to be held at the McCormick Place Convention Center in Chicago, Illinois, April 25-30, 2025. GenSci scientists from the Department of Cancer Research, Department of Antibody Discovery and Protein Engineering, and Department of Medicinal Chemistry will present 7 oncology R&D programs at AACR, a number of which will enter phase 1 clinical trial late this year or early next year (see a summary below).

GenSci is a new comer to the oncology field, but we strive to become an important player in cancer healthcare, both locally and globally, by rapidly discovering, developing, and commercializing efficacious and accessible new medicines that prolong survival and improve quality of life for patients with breast, prostate, ovarian, and other cancer types. We are currently looking for strategic partners to work with us to develop some of our most innovative products for global markets, including antibody-drug conjugates and small molecules.

Please join us, alongside other scientists, clinicians, other health care professionals, patients, survivors, and advocates, to share cutting-edge science, to discuss partnership opportunities, and to advance transformative medicines for cancer patients. Looking forward to seeing you there!